{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:19:32Z","timestamp":1792718372876,"version":"4.5.0"},"reference-count":187,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Candida spp. are common components of normal microbiota in the oral cavity. However, Candida albicans can be a primary cause of superficial infections in the oral cavity and esophagus, especially in immunocompromised individuals. While these infections are rarely life-threatening, they can significantly impair quality of life and, in severe cases, progress to hematogenous dissemination. Oral candidiasis often exhibits as pseudomembranous, erythematous (atrophic), chronic hyperplastic, denture stomatitis, or angular cheilitis. Esophageal candidiasis is typically diagnosed by upper endoscopy, which involves histological examination and brushing. Clinical guidelines recommend topical antifungal agents for mild oral candidiasis, and systemic agents for moderate-to-severe disease or when topical therapy fails. However, azole antifungals pose a substantial risk of drug\u2013drug interactions, primarily due to the inhibition of cytochrome P450 enzymes and drug transporters, which dramatically alters the pharmacokinetics of co-administered drugs. Additionally, amphotericin B, a polyene macrolide antibiotic, may cause nephrotoxicity and electrolyte disturbances (e.g., hypokalemia and hypomagnesemia). Moreover, the co-administration of nephrotoxic drugs may augment the toxicity associated with amphotericin B. Therefore, this review aimed to provide a comprehensive overview of the management of oral and esophageal candidiasis from the viewpoint of clinical pharmacology, with a particular focus on drug\u2013drug interactions and adverse effect profiles.<\/jats:p>","DOI":"10.3390\/jcm14217537","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:48:46Z","timestamp":1761716926000},"page":"7537","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-2068","authenticated-orcid":false,"given":"Toshinori","family":"Hirai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Institute of Science Tokyo Hospital, 1-5-45 Yushima, Bunkyo-ku 113-8519, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5580-6680","authenticated-orcid":false,"given":"Masanori","family":"Nashi","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Nishinomiya Watanabe Hospital, 10-22 Murokawa-cho, Nishinomiya 662-0863, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/apm.13412","article-title":"Pathophysiological microenvironments in oral candidiasis","volume":"132","year":"2024","journal-title":"APMIS"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1574-6976.2011.00278.x","article-title":"Candida glabrata, Candida parapsilosis and Candida tropicalis: Biology, epidemiology, pathogenicity and antifungal resistance","volume":"36","author":"Silva","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.4103\/0973-029X.141325","article-title":"Oral candidiasis: An overview","volume":"18","author":"Singh","year":"2014","journal-title":"J. Oral Maxillofac. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3585136","DOI":"10.1155\/2019\/3585136","article-title":"Diagnosis and Treatment of Esophageal Candidiasis: Current Updates","volume":"2019","author":"Mohamed","year":"2019","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Talapko, J., Juzba\u0161i\u0107, M., Matijevi\u0107, T., Pustijanac, E., Beki\u0107, S., Kotris, I., and \u0160krlec, I. (2021). Candida albicans-The Virulence Factors and Clinical Manifestations of Infection. J. Fungi, 7.","DOI":"10.3390\/jof7020079"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Patil, S., Rao, R.S., Majumdar, B., and Anil, S. (2015). Clinical Appearance of Oral Candida Infection and Therapeutic Strategies. Front. Microbiol., 6.","DOI":"10.3389\/fmicb.2015.01391"},{"key":"ref_8","first-page":"e279","article-title":"Clinical and microbiological diagnosis of oral candidiasis","volume":"5","year":"2013","journal-title":"J. Clin. Exp. Dent."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rich, A.M., Hussaini, H.M., Nizar, M.A.M., Gavidi, R.O., Tauati-Williams, E., Yakin, M., and Seo, B. (2023). Diagnosis of oral potentially malignant disorders: Overview and experience in Oceania. Front. Oral Health, 4.","DOI":"10.3389\/froh.2023.1122497"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.arcmed.2005.05.015","article-title":"Invasive candidiasis in immunocompromised hospitalized patients","volume":"36","author":"Sims","year":"2005","journal-title":"Arch. Med. Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dropulic, L.K., and Lederman, H.M. (2016). Overview of Infections in the Immunocompromised Host. Microbiol. Spectrum., 4.","DOI":"10.1128\/microbiolspec.DMIH2-0026-2016"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/0022034511399284","article-title":"Candida-host interactions in HIV disease: Implications for oropharyngeal candidiasis","volume":"23","author":"Fidel","year":"2011","journal-title":"Adv. Dent. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Teoh, F., and Pavelka, N. (2016). How Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future Directions. Pathogens, 5.","DOI":"10.3390\/pathogens5010006"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1111\/j.1600-6143.2009.02909.x","article-title":"Candida in solid organ transplant recipients","volume":"9","author":"Pappas","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Peri\u0107, M., Mili\u010di\u0107, B., Kuzmanovi\u0107 Pfi\u0107er, J., \u017divkovi\u0107, R., and Arsi\u0107 Arsenijevi\u0107, V. (2024). A Systematic Review of Denture Stomatitis: Predisposing Factors, Clinical Features, Etiology, and Global Candida spp. Distribution. J. Fungi, 10.","DOI":"10.3390\/jof10050328"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/odi.13151","article-title":"Oral Candida colonization in xerostomic postradiotherapy head and neck cancer patients","volume":"25","author":"Tarapan","year":"2019","journal-title":"Oral Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41415-023-5864-z","article-title":"The dental management of patients irradiated for head and neck cancer","volume":"234","author":"Goh","year":"2023","journal-title":"Br. Dent. J."},{"key":"ref_18","first-page":"e391","article-title":"Oral lesions in Sjogren\u2019s syndrome: A systematic review","volume":"23","author":"Serrano","year":"2018","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s41182-024-00649-6","article-title":"Distribution of Candida species isolated from people living with human immunodeficiency virus with oropharyngeal and oral candidiasis in Africa in the era of universal test and treat policy: A systematic review and meta-analysis","volume":"52","author":"Musinguzi","year":"2024","journal-title":"Trop. Med. Health"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13054-020-2793-y","article-title":"Factors associated with the development of septic shock in patients with candidemia: A post hoc analysis from two prospective cohorts","volume":"24","author":"Bassetti","year":"2020","journal-title":"Crit. Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/cid\/ciac004","article-title":"Attributable Mortality of Candida Bloodstream Infections in the Modern Era: A Propensity Score Analysis","volume":"75","author":"Mazi","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejim.2016.06.029","article-title":"Candidemia and invasive candidiasis in adults: A narrative review","volume":"34","author":"Antinori","year":"2016","journal-title":"Eur. J. Intern. Med."},{"key":"ref_23","first-page":"758394","article-title":"What Makes Oral Candidiasis Recurrent Infection? A Clinical View","volume":"2014","author":"Darwazeh","year":"2014","journal-title":"J. Mycol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/dmd.122.001066","article-title":"Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine","volume":"51","author":"Jackson","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41579-021-00578-9","article-title":"Optimizing antimicrobial use: Challenges, advances and opportunities","volume":"19","author":"Rawson","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Carmo, A., Rocha, M., Pereirinha, P., Tom\u00e9, R., and Costa, E. (2023). Antifungals: From Pharmacokinetics to Clinical Practice. Antibiotics, 12.","DOI":"10.3390\/antibiotics12050884"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Silva, S., Rodrigues, C.F., Ara\u00fajo, D., Rodrigues, M.E., and Henriques, M. (2017). Candida Species Biofilms\u2019 Antifungal Resistance. J. Fungi, 3.","DOI":"10.3390\/jof3010008"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kaur, J., and Nobile, C.J. (2023). Antifungal drug-resistance mechanisms in Candida biofilms. Curr. Opin. Microbiol., 71.","DOI":"10.1016\/j.mib.2022.102237"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1002\/cncr.33100","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"126","author":"Elad","year":"2020","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Patel, M. (2022). Oral Cavity and Candida albicans: Colonisation to the Development of Infection. Pathogens, 11.","DOI":"10.3390\/pathogens11030335"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1532-849X.2010.00674.x","article-title":"Evidence-based guidelines for the care and maintenance of complete dentures: A publication of the American College of Prosthodontists","volume":"20","author":"Felton","year":"2011","journal-title":"J. Prosthodont."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41415-022-4397-1","article-title":"Denture cleanliness and hygiene: An overview","volume":"233","author":"Mylonas","year":"2022","journal-title":"Br. Dent. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1368-8375(98)00109-2","article-title":"A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy","volume":"35","author":"Epstein","year":"1999","journal-title":"Oral Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1741-2358.2006.00120.x","article-title":"Relationship between salivary histatin 5 levels and Candida CFU counts in healthy elderly","volume":"23","author":"Sugimoto","year":"2006","journal-title":"Gerodontology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/08959374000140010201","article-title":"Salivary histatin 5 and its similarities to the other antimicrobial proteins in human saliva","volume":"14","author":"Edgerton","year":"2000","journal-title":"Adv. Dent. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/154405910808700411","article-title":"Oral manifestations of Sj\u00f6gren\u2019s syndrome","volume":"87","author":"Mathews","year":"2008","journal-title":"J. Dent. Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lu, S.Y. (2021). Oral Candidosis: Pathophysiology and Best Practice for Diagnosis, Classification, and Successful Management. J. Fungi, 7.","DOI":"10.3390\/jof7070555"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/jopr.12551","article-title":"Status of Removable Dentures and Relationship with Oral Candida-Associated Factors in a Geriatric Population in Catalonia","volume":"26","author":"Martori","year":"2017","journal-title":"J. Prosthodont."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2842.2007.01754.x","article-title":"Relationship between Candida and nocturnal denture wear: Quantitative study","volume":"34","author":"Compagnoni","year":"2007","journal-title":"J. Oral Rehabil."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jama.2024.0953","article-title":"Common Oral Conditions: A Review","volume":"331","author":"Stoopler","year":"2024","journal-title":"Jama"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-016-0153-9","article-title":"A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI","volume":"17","author":"Wolff","year":"2017","journal-title":"Drugs R D"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.21.01208","article-title":"Salivary Gland Hypofunction and\/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO\/MASCC\/ASCO Guideline","volume":"39","author":"Mercadante","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/ger.12347","article-title":"Oral hypofunction in the older population: Position paper of the Japanese Society of Gerodontology in 2016","volume":"35","author":"Minakuchi","year":"2018","journal-title":"Gerodontology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/archinte.1979.03630430036012","article-title":"Oropharyngeal candidiasis treated with a troche form of clotrimazole","volume":"139","author":"Yap","year":"1979","journal-title":"Arch. Intern. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00126334-200402010-00007","article-title":"Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis","volume":"35","author":"Haxaire","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1310\/hct1104-186","article-title":"Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: Study of miconazole Lauriad\u00ae efficacy and safety (SMiLES)","volume":"11","author":"Vazquez","year":"2010","journal-title":"HIV Clin. Trials"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1067\/moe.2001.116600","article-title":"A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients","volume":"92","author":"Patton","year":"2001","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0266-4356(96)90130-8","article-title":"A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours","volume":"34","author":"Finlay","year":"1996","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1086\/513664","article-title":"Oropharyngeal candidiasis in patients with AIDS: Randomized comparison of fluconazole versus nystatin oral suspensions","volume":"24","author":"Pons","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.34.11.2267","article-title":"Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus","volume":"34","author":"Koletar","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1089\/088922299309919","article-title":"Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients","volume":"15","author":"Saag","year":"1999","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1086\/511039","article-title":"Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection","volume":"44","author":"Skiest","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","first-page":"2227","article-title":"Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS","volume":"12","author":"Hegener","year":"1998","journal-title":"Aids"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000239459","article-title":"Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients","volume":"42","author":"Lake","year":"1996","journal-title":"Chemotherapy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbamem.2018.11.006","article-title":"The pore-forming action of polyenes: From model membranes to living organisms","volume":"1861","author":"Kristanc","year":"2019","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002329900086","article-title":"Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions","volume":"152","author":"Ramos","year":"1996","journal-title":"J. Membr. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/jac\/dkac351","article-title":"Liposomal amphotericin B\u2014The past","volume":"77","author":"Jensen","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/CMR.12.1.40","article-title":"Current and emerging azole antifungal agents","volume":"12","author":"Sheehan","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","article-title":"Echinocandins\u2014Structure, mechanism of action and use in antifungal therapy","volume":"37","author":"Chmielewska","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0609.2004.00239.x","article-title":"Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies\u2014A randomized, controlled trial","volume":"72","author":"Martino","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Haro-Reyes, T., D\u00edaz-Peralta, L., Galv\u00e1n-Hern\u00e1ndez, A., Rodr\u00edguez-L\u00f3pez, A., Rodr\u00edguez-Fragoso, L., and Ortega-Blake, I. (2022). Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications. Membranes, 12.","DOI":"10.3390\/membranes12070681"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Mroczy\u0144ska, M., and Brillowska-D\u0105browska, A. (2020). Review on Current Status of Echinocandins Use. Antibiotics, 9.","DOI":"10.3390\/antibiotics9050227"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1469-0691.2009.02913.x","article-title":"Antifungal pharmacokinetics and pharmacodynamics: Bridging from the bench to bedside","volume":"15","author":"Hope","year":"2009","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: Focus on drugs without a clear recommendation","volume":"26","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: Side effects and toxicity","volume":"26","year":"2009","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal Amphotericin B (AmBisome(\u00ae)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","first-page":"163","article-title":"Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections","volume":"6","author":"Falci","year":"2013","journal-title":"Infect. Drug Resist."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","article-title":"The clinical pharmacokinetics of itraconazole: An overview","volume":"32","author":"Heykants","year":"1989","journal-title":"Mycoses"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New Perspectives on Antimicrobial Agents: Isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Alffenaar","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/0091270010395510","article-title":"Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers","volume":"52","author":"Lee","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.2010.03680.x","article-title":"Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: An overview","volume":"70","author":"Lipp","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2217\/fmb.11.19","article-title":"Current perspectives on echinocandin class drugs","volume":"6","author":"Perlin","year":"2011","journal-title":"Future Microbiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1517\/14656566.8.8.1155","article-title":"The echinocandin micafungin: A review of the pharmacology, spectrum of activity, clinical efficacy and safety","volume":"8","author":"Wiederhold","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/infdis\/156.5.784","article-title":"Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B","volume":"156","author":"Gigliotti","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/clinids\/20.4.755","article-title":"Pretreatment regimens for adverse events related to infusion of amphotericin B","volume":"20","author":"Goodwin","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1093\/jac\/dkn394","article-title":"Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: Data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry","volume":"62","author":"Paterson","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2165\/00002018-199005020-00003","article-title":"Amphotericin B nephrotoxicity","volume":"5","author":"Sabra","year":"1990","journal-title":"Drug Saf."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/cid\/ciz064","article-title":"Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin, B","volume":"68","author":"Lewis","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2215\/CJN.12791216","article-title":"Polyuria in a Patient with Aspergillus Infection","volume":"12","author":"Rosner","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.ackd.2018.05.003","article-title":"Hypokalemic Distal Renal Tubular Acidosis","volume":"25","author":"Batlle","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: A systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","article-title":"Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants","volume":"26","author":"Saad","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"106587","DOI":"10.1016\/j.ijantimicag.2022.106587","article-title":"Reducing the off-target endocrinologic adverse effects of azole antifungals-can it be done?","volume":"59","author":"Balcerek","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1248\/bpb.b12-00002","article-title":"Blockade of K+ and Ca2+ channels by azole antifungal agents in neonatal rat ventricular myocytes","volume":"35","author":"Sung","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1086\/508873","article-title":"Antimicrobial-associated QT interval prolongation: Pointes of interest","volume":"43","author":"Owens","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT Interval Shortening with Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current concepts in antifungal pharmacology","volume":"86","author":"Lewis","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.2147\/IDR.S391022","article-title":"Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold\u2014A Retrospective Cohort Study","volume":"15","author":"Yang","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S604","DOI":"10.1093\/cid\/civ814","article-title":"Echinocandins: The Expanding Antifungal Armamentarium","volume":"61","author":"Petraitiene","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0253-7613.62396","article-title":"Echinocandins: A ray of hope in antifungal drug therapy","volume":"42","author":"Grover","year":"2010","journal-title":"Indian J. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"ref_99","first-page":"149","article-title":"Clinical hepatotoxicity associated with antifungal agents","volume":"16","author":"Kyriakidis","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_100","first-page":"170","article-title":"Hepatotoxicity of antifungal agents","volume":"6","author":"Song","year":"2005","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40262-021-01001-5","article-title":"Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes","volume":"60","author":"Song","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/jpet.116.233635","article-title":"Physiological Content and Intrinsic Activities of 10 Cytochrome P450 Isoforms in Human Normal Liver Microsomes","volume":"358","author":"Zhang","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie\u201d","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/pr.113.007518","article-title":"Transporters and drug-drug interactions: Important determinants of drug disposition and effects","volume":"65","author":"Fromm","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cpt.2348","article-title":"Drug-Drug-Gene Interactions: A Call for Clinical Consideration","volume":"110","author":"Bruckmueller","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41397-019-0122-0","article-title":"Drug\u2013drug\u2013gene interactions and adverse drug reactions","volume":"20","author":"Malki","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cpt.1529","article-title":"Prolonged-Release Tacrolimus Is Less Susceptible to Interaction with the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers","volume":"106","author":"Huppertz","year":"2019","journal-title":"Clin. Pharmacol Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.46.9.3091-3093.2002","article-title":"Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes","volume":"46","author":"Venkataramanan","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1111\/bcp.15385","article-title":"The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients","volume":"88","author":"Huang","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jcph.605","article-title":"Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole","volume":"56","author":"Imamura","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jac\/dkae103","article-title":"Triazole antifungal drug interactions-practical considerations for excellent prescribing","volume":"79","author":"Lewis","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","article-title":"Management of drug and food interactions with azole antifungal agents in transplant recipients","volume":"30","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jcph.562","article-title":"Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies","volume":"56","author":"Liu","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s13318-022-00790-9","article-title":"Dual Inhibition of CYP3A4 by Voriconazole and Clarithromycin Influences Tacrolimus Pharmacokinetics: Case Series Study","volume":"47","author":"Hirai","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/0003088-200847120-00003","article-title":"The enzymatic basis of drug-drug interactions with systemic triazole antifungals","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","article-title":"Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone","volume":"58","author":"Kinnunen","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00228-010-0968-1","article-title":"Effects of voriconazole co-administration on oxycodone-induced adverse events: A case in the retrospective survey","volume":"67","author":"Watanabe","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00228-007-0398-x","article-title":"Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl","volume":"64","author":"Saari","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-2003-44457","article-title":"Warfarin and other coumarin derivatives: Pharmacokinetics, pharmacodynamics, and drug interactions","volume":"3","author":"Wittkowsky","year":"2003","journal-title":"Semin. Vasc. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/cpt1974154424","article-title":"Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man","volume":"15","author":"Breckenridge","year":"1974","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cpt1974162348","article-title":"Studies on the optical enantiomorphs of warfarin in man","volume":"16","year":"1974","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","article-title":"Human P450 metabolism of warfarin","volume":"73","author":"Kaminsky","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0006-2952(97)00304-3","article-title":"Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers","volume":"54","author":"Yamazaki","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.2008.150","article-title":"Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: Interactions and the risk of hospitalization for gastrointestinal bleeding","volume":"84","author":"Schelleman","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0090-9556(25)07369-6","article-title":"Warfarin-fluconazole. II. A metabolically based drug interaction: In vivo studies","volume":"24","author":"Black","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2125.2003.01995.x","article-title":"Voriconazole potentiates warfarin-induced prothrombin time prolongation","volume":"56","author":"Purkins","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.bdj.4811224","article-title":"Miconazole oral gel and drug interactions","volume":"196","author":"Pemberton","year":"2004","journal-title":"Br. Dent. J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/87551225211069490","article-title":"Topical Miconazole Cream and Warfarin Interaction: A Case Report","volume":"38","author":"Naberhaus","year":"2022","journal-title":"J. Pharm. Technol."},{"key":"ref_132","first-page":"421","article-title":"Topical use of miconazole antifungal oral gel on warfarinized patients: A word of caution","volume":"24","author":"Wojnarowska","year":"1997","journal-title":"Dent. Update"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug-Drug Interactions with Direct Oral Anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/bcp.13934","article-title":"Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers","volume":"85","author":"Brings","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2021.04.003","article-title":"Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians","volume":"134","author":"Terrier","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_137","first-page":"e007956","article-title":"Drug Interactions Affecting Oral Anticoagulant Use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/bmc.1128","article-title":"Clopidogrel: Review of bioanalytical methods, pharmacokinetics\/pharmacodynamics, and update on recent trends in drug-drug interaction studies","volume":"23","author":"Mullangi","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/dmd.105.007989","article-title":"Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450","volume":"34","author":"Rehmel","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","article-title":"Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently","volume":"81","author":"Farid","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/21556660.2013.785413","article-title":"Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers","volume":"2","author":"Teng","year":"2013","journal-title":"J. Drug Assess."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-197702010-00001","article-title":"Clinical pharmacokinetics of digoxin","volume":"2","author":"Iisalo","year":"1977","journal-title":"Clin. Pharmacokinet."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00007691-199712000-00001","article-title":"Itraconazole decreases renal clearance of digoxin","volume":"19","author":"Jalava","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1053\/ajkd.2001.21363","article-title":"Coadministration of digoxin with itraconazole in renal transplant recipients","volume":"37","author":"Mathis","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1177\/1078155218801055","article-title":"Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein","volume":"25","author":"Shumaker","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1002\/bcp.70075","article-title":"Population pharmacokinetic analysis of the interaction of digoxin with N-desethylamiodarone in patients with atrial fibrillation and heart failure","volume":"91","author":"Hirai","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxlet.2019.08.003","article-title":"The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism","volume":"315","author":"McGraw","year":"2019","journal-title":"Toxicol. Lett."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.118.084897","article-title":"Pharmacokinetics, Metabolism, and Excretion of [(14)C] Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans","volume":"47","author":"Yamada","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/HJH.0000000000003372","article-title":"Hyperkalemia by eplerenone or esaxerenone in the presence or absence of clarithromycin in hypertensive patients: A retrospective observational cohort study","volume":"41","author":"Hirai","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Zheng, E., Madura, P., Grandos, J., Broncel, M., Pawlos, A., Wo\u017aniak, E., and Gorzelak-Pabi\u015b, P. (2024). When the same treatment has different response: The role of pharmacogenomics in statin therapy. Biomed. Pharmacother., 170.","DOI":"10.1016\/j.biopha.2023.115966"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","article-title":"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole","volume":"63","author":"Neuvonen","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/14622416.6.4.323","article-title":"The pharmacogenetics of calcineurin inhibitors: One step closer toward individualized immunosuppression?","volume":"6","author":"Hesselink","year":"2005","journal-title":"Pharmacogenomics"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2013.05.033","article-title":"From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation","volume":"452","author":"Knops","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"101756","DOI":"10.1016\/j.bpg.2021.101756","article-title":"Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology","volume":"54-55","author":"Udomkarnjananun","year":"2021","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/00007890-199105000-00016","article-title":"Interaction between cyclosporine and fluconazole in renal allograft recipients","volume":"51","author":"Canafax","year":"1991","journal-title":"Transplantation"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/106002809302700405","article-title":"Fluconazole-cyclosporine interaction: A dose-dependent effect?","volume":"27","year":"1993","journal-title":"Ann. Pharmacother."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"6850289","DOI":"10.1155\/2024\/6850289","article-title":"Effects of Triazole Antifungal Agents on the Plasma Concentration and Dosage of Cyclosporin in Patients with Aplastic Anaemia","volume":"2024","author":"Tian","year":"2024","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","article-title":"Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus","volume":"51","author":"Kamdem","year":"2005","journal-title":"Clin. Chem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/10781552211029046","article-title":"Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations","volume":"28","author":"Gu","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1111\/ajt.14232","article-title":"Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole\/Posaconazole in Solid Organ Recipients","volume":"17","author":"Vanhove","year":"2017","journal-title":"Am. J. Transpl."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12185-016-2135-7","article-title":"Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation","volume":"105","author":"Suetsugu","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2125.2001.01372.x","article-title":"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects","volume":"51","author":"Archer","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole with the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00280-019-03884-5","article-title":"Aspects of vincristine-induced neuropathy in hematologic malignancies: A systematic review","volume":"84","author":"Madsen","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","article-title":"Interaction of common azole antifungals with P glycoprotein","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrc1887","article-title":"Drug interactions in cancer therapy","volume":"6","author":"Scripture","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"van Leeuwen, R.W., van Gelder, T., Mathijssen, R.H., and Jansman, F.G. (2014). Drug-drug interactions with tyrosine-kinase inhibitors: A clinical perspective. Lancet Oncol., 15.","DOI":"10.1016\/S1470-2045(13)70579-5"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1007\/s11033-023-08573-4","article-title":"Drug induced nephrotoxicity- A mechanistic approach","volume":"50","author":"Sharma","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jac\/43.2.267","article-title":"Risk factors for amphotericin B-induced nephrotoxicity","volume":"43","author":"Luber","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Takazono, T., Tashiro, M., Ota, Y., Obata, Y., Wakamura, T., Miyazaki, T., Nishino, T., and Izumikawa, K. (2020). Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-72135-y"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Stanzani, M., Vianelli, N., Cavo, M., Maritati, A., Morotti, M., and Lewis, R.E. (2017). Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02651-16"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2021.09.029","article-title":"Diuretics in States of Volume Overload: Core Curriculum 2022","volume":"80","author":"Novak","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1053\/j.akdh.2024.08.001","article-title":"Potassium Homeostasis","volume":"31","author":"Desai","year":"2024","journal-title":"Adv. Kidney Dis. Health"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1248\/bpb.b20-00476","article-title":"Geriatric Patients Are at a High Risk of Hypokalemia Associated with Yokukansan Preparation: A Retrospective Cohort Study","volume":"43","author":"Hirai","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_179","first-page":"185","article-title":"Medication-induced hypokalemia","volume":"40","author":"Veltri","year":"2015","journal-title":"PT"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Orofiamma, L.A., Vural, D., and Antonescu, C.N. (2022). Control of cell metabolism by the epidermal growth factor receptor. Biochim. Biophys. Acta Mol. Cell Res., 1869.","DOI":"10.1016\/j.bbamcr.2022.119359"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Hsieh, M.C., Wu, C.F., Chen, C.W., Shi, C.S., Huang, W.S., and Kuan, F.C. (2018). Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: A systematic review and meta-analysis. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-19835-8"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"154","DOI":"10.34067\/KID.0005622020","article-title":"Hypomagnesemia in the Cancer Patient","volume":"2","author":"Workeneh","year":"2021","journal-title":"Kidney360"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1681\/ASN.2007070792","article-title":"Mechanism of hypokalemia in magnesium deficiency","volume":"18","author":"Huang","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.mayocp.2022.12.002","article-title":"Acquired Disorders of Hypomagnesemia","volume":"98","author":"Rosner","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"S445","DOI":"10.1093\/infdis\/jix131","article-title":"Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment","volume":"216","author":"Arendrup","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3109\/1040841X.2011.585606","article-title":"Oral candidosis\u2014clinical challenges of a biofilm disease","volume":"37","author":"Rautemaa","year":"2011","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Akbar, Z., Aamir, M., and Saleem, Z. (2024). Optimizing antifungal therapy: A systematic review of pharmacist interventions, stewardship approaches, and outcomes. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1489109"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7537\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:17:23Z","timestamp":1761718643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":187,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14217537"],"URL":"https:\/\/doi.org\/10.3390\/jcm14217537","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}